Synonyms: AG-881 | AG881 | Voranigo®
vorasidenib is an approved drug (FDA (2024))
Compound class:
Synthetic organic
Comment: Vorasidenib (AG-881) inhibits mutant forms of the isocitrate dehydrogenases (IDH1 and IDH2) [3] that catalyse the generation of the oncogenic metabolite d-2-hydroxyglutarate (2-HG). This compound and others, and their use for treating cancer are claimed in patent US10028961 [4]. Vorasidenib can cross the blood-brain barrier, and is being proposed as a chemotherapeutic for IDH mutation +ve cancers including gliomas [2,8] and hematological malignancies [1]. X-ray cocrystal structures of vorasidenib with mutant IDH1 and mutant IDH2 have been deposited with the RCSB Protein Data Bank [3,5]. The X-ray structures show that vorasidenib binds at an allosteric pocket formed in IDH homodimers, at the interface of the two monomers.
|
|
Classification ![]() |
|
Compound class | Synthetic organic |
Approved drug? | Yes (FDA (2024)) |
Approved drug? | Yes. |
IUPAC Name ![]() |
6-(6-chloropyridin-2-yl)-2-N,4-N-bis[(2R)-1,1,1-trifluoropropan-2-yl]-1,3,5-triazine-2,4-diamine |
International Nonproprietary Names ![]() |
|
INN number | INN |
10525 | vorasidenib |
Synonyms ![]() |
AG-881 | AG881 | Voranigo® |
Database Links ![]() |
|
BindingDB Ligand | 279948 |
CAS Registry No. | 1644545-52-7 (source: WHO INN record) |
GtoPdb PubChem SID | 404859110 |
PubChem CID | 117817422 |
RCSB PDB Ligand | 9UO |
Search Google for chemical match using the InChIKey | QCZAWDGAVJMPTA-RNFRBKRXSA-N |
Search Google for chemicals with the same backbone | QCZAWDGAVJMPTA |
Search PubMed clinical trials | vorasidenib |
Search PubMed titles | vorasidenib |
Search PubMed titles/abstracts | vorasidenib |
UniChem Compound Search for chemical match using the InChIKey | QCZAWDGAVJMPTA-RNFRBKRXSA-N |
UniChem Connectivity Search for chemical match using the InChIKey | QCZAWDGAVJMPTA-RNFRBKRXSA-N |